Prognosis of patients with a second relapse of acute myeloid leukemia
Authors:
Open Access
- 1 December 2000
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 14 (12) , 2059-2063
Abstract
Recurrence of the disease is the major problem in the treatment of acute myeloid leukemia (AML). The majority of patients who achieve a second remission will ultimately relapse. In this retrospective single-center study, we have analyzed the outcome of patients with a second relapse and tried to define the prognostic factors in intensively treated patients. Of 534 patients with AML, 62 had a second relapse. Thirty-three received further intensive chemotherapy (CT). Eighteen patients (55%) achieved a third complete remission (CR). The early death (ED) rate was only 9%. The overall survival (OS) of treated vs untreated patients was 6.9 vs 1.3 months, respectively (P = 0.01). the major selection criteria for a third ct were a favourable (t(15;17),t(8;21),inv(16)) or normal karyotype, long (>11 months) second CR (P ⩽ 0.005) and no previous bone marrow transplantation (BMT)(P < 0.01). favorable or normal karyotype, second cr >11 months, as well as no previous BMT (P < 0.01) were associated with the achievement of a third CR. Favorable (P < 0.005) or normal karyotype (P < 0.01), as well as a second cr >11 months (P < 0.005) were associated with prolonged survival after ct. the median os for patients receiving ct with favorable or normal cytogenetics, a second cr > 11 months, but no previous BMT was 26.5 months. Five patients with favorable or normal karyotype achieved a fourth or fifth remission. We conclude that intensive CT is associated with a survival benefit and good quality of life if patients are properly selected.Keywords
This publication has 20 references indexed in Scilit:
- Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalitiesLeukemia, 2000
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparisonLeukemia, 1998
- An evaluation of combinations of diaziquone, etoposide and mitoxantrone in the treatment of adults with relapsed or refractory acute myeloid leukemia: results of 8722, a randomized phase II study conducted by Cancer and Leukemia Group BLeukemia, 1998
- The significance of trisomy 8 in de novo acute myeloid leukaemia: the accompanying chromosome aberrations determine the prognosisBritish Journal of Haematology, 1997
- Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17)(q22;q21): a report on 50 patientsBritish Journal of Haematology, 1996
- Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center studyAnnals of Hematology, 1996
- Intensive Postremission Chemotherapy in Adults with Acute Myeloid LeukemiaNew England Journal of Medicine, 1994
- The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen‐year periodBritish Journal of Haematology, 1993
- Proposed Revised Criteria for the Classification of Acute Myeloid LeukemiaAnnals of Internal Medicine, 1985